Monday, September 13, 2021 Daily Archives

How to Find Expression and Purification Conditions That Result in High Levels of Thermally Stable Membrane Proteins

by

It’s very common to experience low expression levels when producing membrane proteins — plus they’re finicky and unstable when they’re outside of their native environment. Just know, you’re not alone. In this webinar, we’ll introduce you to the latest technology and techniques that will help you: More easily find the best expression and purification conditions that yield properly folded membrane proteins, saving you time and resources in producing membrane proteins that are stable and functional for downstream use Characterize the…

September 13, 2021

Sandoz expands biosimilar pipeline in Bio-Thera collaboration

by

Sandoz has bolstered  its biosimilar pipeline by entering into a commercialization agreement with Bio-Thera for cancer treatment drug, bevacizumab.    The deal, sees Sandoz (a Novartis division) and Chinese firm Bio-Thera Solutions partner to commercialize BAT1706, a biosimilar of Avastin (bevacizumab) . “We see external collaborations as complementary to our internal programs, with an appropriate strategic balance enabling us to drive patient access by delivering portfolio breadth, balancing risks and costs and positioning us to play a leading role in…

September 13, 2021

Moderna contracts Resilience as it eyes 3 billion doses of COVID vax

by

With continued rollout and boosters on the horizon, Moderna has added space at CDMO Resilience’s Ontario, Canada site to its mRNA COVID-19 vaccine production network. No financial details have been divulged, but the multi-year deal will see contract development and manufacturing organization (CDMO) National Resilience produce mRNA for the Moderna COVID-19 vaccine at its facility in Mississauga, Ontario in Canada. Resilience added the 136,000 square-foot facility through the quiet acquisition of assets from Therapure Biopharma, and while Moderna told this publication it…

September 13, 2021